New Technology– category –
-
ChemCopilot’s Generative AI Translates Natural Language to SMILES, Automating Molecular Design
ChemCopilot Unknown Overview ChemCopilot has launched a groundbreaking generative AI model for molecular design, capable of translating natural language prompts into stable SMILES strings. This innovative system automates the entire work... -
Efficient Prime Editing In Vivo and In Vitro Demonstrated with Lipid Nanoparticles: High Efficacy, Low Off-Target Effects
PubMed International Overview Recent research reports the development of an optimized platform for prime editing using lipid nanoparticles (PE-LNP), demonstrating high gene editing efficiency in vivo. This LNP-based system offers a compe... -
Bispecific Antibody Ivonescimab Plus Chemotherapy Significantly Improves Overall Survival in EGFR-Mutant NSCLC: HARMONi-A Phase 3 Results Published in JAMA
PubMed (JAMA) International Overview Final results from the Phase 3 HARMONi-A clinical trial, published in JAMA, demonstrate a breakthrough in EGFR-mutant non-small cell lung cancer (NSCLC) treatment. Combination therapy with the bispeci... -
University of Houston Discovers ‘Salt-Loaded LNPs’ to Overcome Major Gene Therapy Obstacle by Enhancing Endosomal Escape
University of Houston USA Overview Researchers at the University of Houston have made a groundbreaking discovery to improve intracellular delivery of genetic material, a major hurdle in gene therapy. They developed 'salt-loaded lipid nan... -
Boltz Forms AI Drug Discovery Partnership with Takeda to Boost Molecular Design with Novel Biomolecular Foundation Models
FirstWord HEALTHTECH Japan Overview Boltz has announced a strategic AI drug discovery partnership with Takeda Pharmaceutical Company. This collaboration will integrate Boltz's new biomolecular foundation models, BoltzMol-1 for small mole... -
Antibody-Drug Conjugate (ADC) Field Enters Era of Diversification in 2025: 130 New ADC Candidates Advance to Clinical Development, Total Reaches 2,334
ChemExpress (citing Beacon ADC database) China Overview In 2025, the Antibody-Drug Conjugate (ADC) field experienced a significant paradigm shift, transitioning from platform validation to an era of diversification. The total number of t... -
Solu Therapeutics’ STX-0712 with CyTAC™ Technology Granted FDA Fast Track for Relapsed or Refractory CMML
Pharma News (citing Solu Therapeutics) USA Overview Solu Therapeutics announced that STX-0712, utilizing its CyTAC™ technology, received FDA Fast Track designation for relapsed or refractory chronic myelomonocytic leukemia (CMML). STX-07... -
NovaBridge Biosciences’ Givastomig Secures FDA Fast Track for HER2-Negative Metastatic Gastric Cancer
Cancer Network (citing NovaBridge Biosciences) USA Overview NovaBridge Biosciences' CLDN18.2 x 4-1BB bispecific antibody, givastomig, has received FDA Fast Track designation for HER2-negative metastatic gastric cancer. This designation i... -
Insilico Medicine Initiates Phase 1 Trial for AI-Designed Brain-Penetrant NLRP3 Inhibitor ISM8969 for Neuroinflammation
World Pharma Today Hong Kong Overview Insilico Medicine has completed dosing of the first patient in a Phase 1 trial for ISM8969, an AI-designed brain-penetrant NLRP3 inhibitor targeting neuroinflammatory and CNS diseases like Parkinson'... -
Biogen’s Salanersen Granted FDA Breakthrough Therapy Designation for SMA Patients with Suboptimal Gene Therapy Response
Cure SMA USA Overview Biogen's investigational spinal muscular atrophy (SMA) therapy, salanersen, has received Breakthrough Therapy Designation from the FDA. This designation is based on promising Phase 1b data in pediatric SMA patients ...
